Electrophysiologic effects of nicorandil on the guinea pig long QT1 syndrome model

Journal of Cardiovascular Electrophysiology

Volumn 15, Issue 7, 2004, Pages 815-820

  Yang, Zhifang ^a   Shi, Guozhong ^a   Li, Cizheng ^a   Wang, Hongwei ^a   Liu, Kai ^a   Liu, Yuanmou ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Action potential; Chromanol 293B; Electrocardiography; Guinea pig; Long QT1 syndrome; Nicorandil

Indexed keywords

CHROMANOL 293B; INWARDLY RECTIFYING POTASSIUM CHANNEL; NICORANDIL; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL MODEL; FEMALE; GUINEA PIG; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART REPOLARIZATION; HEART RIGHT VENTRICLE; HEART VENTRICLE FIBRILLATION; IN VITRO STUDY; IN VIVO STUDY; LONG QT SYNDROME; MALE; MEMBRANE POTENTIAL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; QT INTERVAL;

ACTION POTENTIALS; ANIMALS; CHROMANS; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; GUINEA PIGS; LONG QT SYNDROME; NICORANDIL; POTASSIUM CHANNEL BLOCKERS; SULFONAMIDES; VASODILATOR AGENTS;

EID: 3242712922     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2004.03632.x     Document Type: Article

References (15)

1. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580.
2. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V: Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003;421:634-639.
3. Roden DM, Spooner PM: Inherited long QT syndromes: A paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol 1999;10:1664-1683.
4. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT: Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996;384:80-83.
5. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Toubin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12:17-23.
6. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, Rubie C, Hordt M, Towbin JA, Borggrefe M, Assmann G, Qu X, Somberg JC, Breithardt G, Oberti C, Funke H: KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet 1997;17:267-268.
7. + channel opener in the LQT1 form of congenital long-QT syndrome. Circulation 1998;97:1581-1588.
8. Shimizu W, Antzelevitch C: Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000;102:706-712.
9. Sun ZQ, Thomas GP, Antzelevitch C: Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J Cardiovasc Electrophysiol 2001;12:472-478.
10. Roden DM, Anderson ME: The pause that refreshes, or does it? Mechanisms in torsades de pointes. Heart 2000;84:235-237.
11. Falase B, Easaw J, Youhana A: The role of nicorandil in the treatment of myocardial ischaemia. Expert Opin Pharmacother 2001;2:845-856.
12. Fujimoto Y, Morita H, Fukushima KK, Ohe T: Nicorandil abolished repolarisation alternans in a patient with idiopathic long QT syndrome. Heart 1999;82:e8.
13. Watanabe O, Okumura T, Takeda H, Nakamura W, Segawa K, Ito H, Yoshimoto N: Nicorandil, a potassium channel opener, abolished torsades de pointes in a patient with complete atrioventricular block. Pacing Clin Electrophysiol 1999;22:686-688.
14. + loss in hypoxic and ischaemic mammalian ventricle. J Physiol 1992;447:649-673.
15. Cavero I, Djellas Y, Guillon JM: Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels. Cardiovasc Drugs Ther 1995:9(Suppl 2):245-255.